Your search for apixaban returned 19 results

No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons

Apixaban and rivaroxaban are both factor Xa inhibitors.

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Apixaban is a direct oral anticoagulant that relies less on kidney excretion.

Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban

Improved communication with patients about cost, bleeding, and monitoring may increase compliance

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

Risk up with amiodarone vs flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban.

Asundexian is an investigational oral Factor XIa inhibitor.

Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban